CClinicalTrials.gg
Not yet recruitingNCT07793773Updated Aug 31, 2026

Disease Impact and Its Correlation With Disease Activity in Psoriatic Arthritis

An observational study in Psoriatic Arthritis, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by Assiut University · Observational

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
80
Ages
18 Years and older
Sex
All
01

Study summary

Psoriatic arthritis (PsA) is a chronic inflammatory musculoskeletal disorder that causes joint pain, stiffness, skin lesions, and functional disability, significantly affecting patients' quality of life. Patient-reported outcome measures (PROMs) provide essential insights into the impact of disease from the patient's perspective. The Psoriatic Arthritis Impact of Disease-12 (PsAID-12) questionnaire is a validated tool designed to evaluate 12 physical and psychological aspects of disease burden.

The main purpose of this cross-sectional study is to evaluate disease impact using the Arabic version of the PsAID-12 questionnaire and to investigate how disease impact correlates with clinical disease activity measured by the Disease Activity in Psoriatic Arthritis (DAPSA) score in adult patients with PsA.

Participants will undergo routine clinical and rheumatological evaluations, including joint examinations (tender and swollen joint counts), laboratory tests (complete blood count, inflammatory markers such as ESR and CRP, liver and kidney function tests, and lipid profile), and plain radiography of affected joints (hands, feet, and sacroiliac joints). Patients will also complete the Arabic PsAID-12 questionnaire and patient global and pain assessments. All assessments will take place during a single evaluation visit at Assiut University Hospital.

02

Conditions studied

  • Psoriatic Arthritis

Browse trials for

Keywords

  • PsAID-12
  • DAPSA
  • Disease Activity
  • Patient Reported Outcome Measures
  • Quality of Life
  • CASPAR Criteria
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

All adult patients aged 18 years and older diagnosed with psoriatic arthritis according to the Classification Criteria for Psoriatic Arthritis (CASPAR) who attend the inpatient wards or outpatient clinics of the Rheumatology, Rehabilitation and Physical Medicine Department at Assiut University Hospital during the one-year study period.

Inclusion criteria

  • Patients diagnosed with psoriatic arthritis according to the Classification Criteria for Psoriatic Arthritis (CASPAR) criteria
  • Age ≥ 18 years
  • Willingness to participate in the study and provide informed consent

Exclusion criteria

Exclusion Criteria:

  • Patients younger than 18 years of age
  • Presence of other coexisting autoimmune diseases
  • Patients with advanced malignancy
04

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
80 participants (estimated)
Patient registry
No

Groups and cohorts

  • Psoriatic Arthritis Patients

    Adult patients aged 18 years or older diagnosed with psoriatic arthritis fulfilling the CASPAR (Classification Criteria for Psoriatic Arthritis) criteria who are attending the inpatient or outpatient clinics of the Rheumatology, Rehabilitation and Physical Medicine Department at Assiut University Hospital. Patients undergo evaluation for disease impact using the Arabic 12-item Psoriatic Arthritis Impact of Disease (PsAID-12) questionnaire and assessment of disease activity via the Disease Activity in Psoriatic Arthritis (DAPSA) score.

05

What researchers measure

Primary outcomes

  1. Disease Impact Score Assessed by the Psoriatic Arthritis Impact of Disease (PsAID-12) Questionnaire

    The Arabic version of the Psoriatic Arthritis Impact of Disease 12-item (PsAID-12) questionnaire is used to evaluate patient-reported disease impact. It assesses 12 domains: pain, fatigue, skin problems, work and leisure activities, functional capacity, discomfort, sleep disturbance, coping, anxiety/fear, embarrassment/shame, social participation, and depression. Each domain is scored on a numerical rating scale from 0 to 10, weighted, and aggregated into a total score ranging from 0 (no impact/best status) to 10 (extreme impact/worst status). Higher total scores indicate greater negative disease impact.

    Time frame: Baseline

06

Study locations

No study locations are listed for this record.

07

Registry details

Key details

Study ID
NCT07793773
Lead sponsor
Assiut University
Responsible party
Helana Alkes Zakka Labib Garas (Resident of Rheumatology and Rehabilitation, Assiut University) — Principal investigator
First posted
Aug 31, 2026
Start date
Oct 2026 (estimated)
Primary completion
Oct 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Aug 31, 2026
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion